**TARGET AUDIENCE**
This activity is designed for advanced practitioners, oncology nurses, hematology nurses, advanced practice registered nurses, and other nursing professionals supporting the management of patients with myelofibrosis.

**PURPOSE**
The goal of this activity is to provide advanced practitioners, oncology nurses, hematology nurses, and other nursing professionals with appropriate treatment management strategies for myelofibrosis and the latest clinical evidence to optimally integrate into clinical practice to improve patient outcomes.

**ACTIVITY OVERVIEW**
Myelofibrosis (MF) is a Philadelphia chromosome-negative stem cell myeloproliferative neoplasm (MPN) associated with cytopenias, splenomegaly, constitutional symptoms, poor prognosis, and suboptimal quality of life. A rare condition, it affects approximately 1 in 100,000 people in the US each year. Patients with myelofibrosis commonly express JAK2 V617F mutation and activation of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling. Agents targeting the JAK/STAT pathway have demonstrated efficacy in patients with MF. In order to appropriately manage patients on these therapies, nurses must play a vital role in educating patients. Nursing management includes frequent close monitoring of blood counts for thrombocytopenia, anemia, or leukopenia. Nurses must assess for any bleeding or infection due to decreased counts. Compliance with oral therapy is essential. Dose adjustments may be based on the platelet counts or severity of side effects. Hence, oncology nurses, hematology nurses, and other nursing professionals involved in the treatment and long-term management of patients with myelofibrosis need a thorough understanding of key pathogenic, clinical, and patient features, current and emerging therapeutic strategies to combat the disease, and how to integrate the new agents, regimens, and disease- and therapy-related management strategies into treatment plans to optimize outcomes for individual patients. The proposed series of live activities seeks to address these educational needs while bridging existing knowledge and performance gaps to improve the clinical outcomes of patients with myelofibrosis.

**LEARNING OBJECTIVES**
At the conclusion of this activity, participants should be able to:
- Define and grade myelofibrosis based on current WHO classification and criteria
- Recognize common signs and symptoms associated with myelofibrosis
- Discuss the role of chemotherapeutic agents in the treatment of myelofibrosis, including assessment of their clinical benefits
- Evaluate emerging clinical evidence on the safety and efficacy of novel agents for the therapeutic management of myelofibrosis
- Implement effective symptomatic and side effect management strategies to optimize outcomes for patients treated for myelofibrosis

**CHAIRPERSON**
Sandra E. Kurtin, MS, RN, ANP, AOCN®
The University of Arizona Cancer Center

**ACTIVITY AGENDA**
- Introduction (5 mins)
- Pathogenesis and Clinical Overview of Myelofibrosis (10 mins)
- Current Clinical Management of Myelofibrosis (25 mins)
- Emerging Therapies for the Management of Myelofibrosis (15 mins)
- Question and Answer (5 mins)

There is no fee for this educational activity.
Nursing Strategies In the Management of Myelofibrosis

NURSING CONTINUING MEDICAL EDUCATION

Credit Designation
This educational activity for 1 contact hour(s) is provided by Postgraduate Institute for Medicine. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CALIFORNIA BOARD OF REGISTERED NURSING
Provider is approved by the California Board of Registered Nursing, Provider #13485, for 1 contact hour(s).
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

AMERICANS WITH DISABILITIES ACT
In compliance with the Americans with Disabilities Act, we will make every reasonable effort to accommodate your request. For any special requests, please contact AXIS at 877-238-8666 before the meeting dates.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.”

SAFEGUARDS AGAINST COMMERCIAL BIAS
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME/CE activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME/CE activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education’s and American Nurses Credentialing Center’s Commission (ANCC) on Accreditation’s content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:
1. Fair balance
   a. Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
   b. No single product or service is overrepresented when other equal competing products or services are available for inclusion
2. Scientific objectivity of studies mentioned in the materials or used as the basis for content
3. Appropriateness of patient care recommendations made to learners